Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The Medicines Company
Biotech
Arch-backed obesity biotech launches with $290M
Clinical-stage Metsera has emerged from stealth with $290 million and the bold vision of ushering in the next generation of obesity treatments.
Gabrielle Masson
Apr 18, 2024 7:00am
Ex-Purdue CEO Timney lands at amyloidosis biotech Attralus
May 11, 2021 11:05am
Novartis' inclisiran cuts bad cholesterol levels by at least 30%
Aug 30, 2020 10:39am
Novartis' cholesterol buster, new trials fall victim to COVID-19
Apr 28, 2020 10:40am
Novartis presents pooled inclisiran data cutting LDL by 51%
Mar 28, 2020 2:31pm
Novartis posts pivotal data ahead of FDA decision on $9.7B bet
Mar 19, 2020 7:40am
